Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

NCT00019604 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-02-03

Study results available
· View outcomes & findings →

Summary

RATIONALE: Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have unresectable primary or metastatic liver cancer.

Conditions

Interventions

PROCEDURE

computed tomography

Scan to assess the effects of ablation.

PROCEDURE

magnetic resonance imaging

Imaging used to assess the effects of this ablative therapy on tumor vascular density.

PROCEDURE

positron emission tomography

Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.

PROCEDURE

radiofrequency ablation

Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.

PROCEDURE

radionuclide imaging

Imaging following injection of a radioactive material.

PROCEDURE

ultrasound imaging

An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.

RADIATION

fludeoxyglucose F 18 (FDG-PET)

FDG PET scans rely on metabolic changes to evaluate response to therapy.

RADIATION

gadopentetate dimeglumine

Food and Drug Administration approved contrast agent.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Steven A Libutti, MD · National Cancer Institute, National Institutes of Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00019604 on ClinicalTrials.gov